Next Article in Journal
Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis
Next Article in Special Issue
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Previous Article in Journal
Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center Experience
Previous Article in Special Issue
Preface of the Special Issue “COVID-19 Infection and Hematological Malignancies”
 
 
Article
Peer-Review Record

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy

Cancers 2022, 14(19), 4720; https://doi.org/10.3390/cancers14194720
by Jerzy Jaroszewicz 1,*,†, Justyna Kowalska 2,†, Małgorzata Pawłowska 3, Magdalena Rogalska 4, Dorota Zarębska-Michaluk 5, Marta Rorat 6, Beata Lorenc 7, Piotr Czupryna 8, Katarzyna Sikorska 9, Anna Piekarska 10, Anna Dworzańska 11, Izabela Zaleska 12, Włodzimierz Mazur 13, Dorota Kozielewicz 3, Krzysztof Kłos 14, Regina Podlasin 15, Grzegorz Angielski 16, Barbara Oczko-Grzesik 1, Magdalena Figlerowicz 17, Bartosz Szetela 18, Beata Bolewska 19, Paulina Frańczak-Chmura 20, Robert Flisiak 4 and Krzysztof Tomasiewicz 11add Show full author list remove Hide full author list
Reviewer 1: Anonymous
Reviewer 2:
Cancers 2022, 14(19), 4720; https://doi.org/10.3390/cancers14194720
Submission received: 30 August 2022 / Revised: 19 September 2022 / Accepted: 23 September 2022 / Published: 28 September 2022
(This article belongs to the Special Issue COVID-19 Infection and Hematological Malignancies)

Round 1

Reviewer 1 Report

In this manuscript, the authors present the data on efficacy of Remdesivir in decreasing mortality in covid patients previously diagnosed with different types of cancers. The data is interesting as early use of Remdesivir can reduce up to 80% mortality rate in the patients with Covid19/cancer. Though the study is not complete per se, it presents significant insights on efficacy of antiviral drugs such as Remdesivir in cancer patients when infected with Covid19. The manuscript needs to be proof-read thoroughly for inadvertent typos and language including the abstract section, line 62.

Author Response

Thank you for your comment. The manuscript has undergone a thorough linguistic revision of both spelling and grammar. Individual changes were not marked due to their multiplicity.

Reviewer 2 Report

This is an important study on the effect of remdesivir in COVID-19 patients with active malignancy. It may be more informative if each parameters of male and female are shown in Tables if possible. 

Author Response

Thank you for your comment. In accordance with the comments of the reviewer, an additional table (Supplementary Table 1) has been created which illustrates the initial parameters of the analyzed group depending on gender. A corresponding adnotation has also been added in the results section. Gender was also considered in the final multivariate analysis.

Round 2

Reviewer 1 Report

The authors have significantly improved the manuscript by editing the language and style of presentation. The manuscript may be considered for publication.

Back to TopTop